Citations

Clear

3042 citation(s) found for "Kumar, S".

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Bailey, Janet E., Burstein, Harold J. , Chen, Nan , Chew, Helen K. , Dang, Chau T. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Lyons, Janice A., McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Santa‐Maria, Cesar A. , Schneider, Bryan P. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wei, Mei , Wisinski, Kari B. , Yeung, Kay T. , Schonfeld, Ryan, Telli, Melinda L , Abramson, Vandana G. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Soliman, Hatem Hussein , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 331-357

10.6004/jnccn.2024.0035 | PMID 39019058 Get It

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .
Multisystem Imaging Manifestations of Kidney Failure
Suman, Garima , Vijay, Kanupriya , Venugopal, Nitin , Mansoori, Bahar , Agarwal, Amit , Rajiah, Prabhakar , Vijay, Kanupriya , Venugopal, Nitin , Mansoori, Bahar , Chalian, Majid , Agarwal, Amit Kumar , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | July 25, 2024 | Volume: 44 | Issue: 8 | Pages: No page available

10.1148/rg.230124 | PMID 39052499 Get It

Cardiometabolic Risk Markers in Children With Obesity and Variants in MC4R Pathway-related Genes
Salama, Mostafa , Hentz, Roland, Nofal, Alaa Al , Hassan, Sara, Ibrahim, Samar H. , Lteif, Aida, Creo, Ana L. , Pittock, Siobhán T. , Kumar, Seema , Vairo, Filippo , Creo, Ana , Pittock, Siobhan , Kumar, Seema , Salama, Mostafa , Al Nofal, Alaa , Ibrahim, Samar H , Vairo, Filippo Pinto e

Mayo Clinic

Journal of the Endocrine Society | July 25, 2024 | Volume: 8 | Issue: 9 | Pages: No page available

10.1210/jendso/bvae137 | PMID 39109292 Get It

Abstract Context Variants in melanocortin 4 receptor (MC4R) pathway-related genes have been associated with obesity. The association of these variants with cardiometabolic parameters are not fully known. Objective We compared the severity of obesity and cardiometabolic risk markers in children with MC4R pathway-related clinically reported genetic variants relative to children without these variants. Methods A retrospective chart review was performed in children with obesity who underwent multigene panel testing for monogenic obesity. Results Data on a total of 104 children were examined, with 93 (89%) identified as White. Thirty-nine (37.5%) patients had clinically reported variants in the MC4R pathway, and the remaining 65 patients did not have reported MC4R pathway-related variants. Among the MC4R-related variants, PCSK1 risk alleles were most common, reported in 15 children (14%). The maximum body mass index percent of the 95th percentile was not different between groups (P = .116). Low-density lipoprotein cholesterol (LDL-C) was not different between groups (P = .132). However, subgroup analysis demonstrated higher LDL cholesterol in children with the PCSK1 c.661A>G risk allele relative to those with MC4R-related variant of uncertain significance (P = .047), negative genetic testing (P = .012), and those with non-MC4R related variants (P = .048). The blood pressure, fasting glucose, hemoglobin A1C, total cholesterol, alanine transaminase, and high-density lipoprotein cholesterol were not different between groups. Conclusion Variants in the MC4R pathway-related genes were not associated with severity of obesity and cardiometabolic risk markers except for the c.661A>G PCSK1 risk allele, which was associated with higher LDL-C levels.
Writing Groups for Healthcare Professionals in Academic Medicine
Croghan, Ivana T. , Kumar, Shaji , Raffals, Laura E., Schletty, Anne A., Schroeder, Darrell R. , Gathje, Shelby R., Shah, Vijay H. , Hurt, Ryan T. , Schroeder, Darrel R, Shah, Vijay, Schroeder, Darrell , Dugani, Sagar B. , Raffals, Laura E.

Mayo Clinic

Journal of Primary Care & Community Health | July 25, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241266102 | PMID 39051662 Get It

Within the Department of Medicine (DOM) in a large tertiary academic health care facility in midwestern United States, we have developed an educational offering that incorporates an academic writing program (AWP) blending the approaches of a writing accountability work group, a writing workshop, and didactic writing courses. The purpose of this AWP was to assist healthcare professionals (HCP) with their manuscript writing skills to enhance academic productivity. We report our evolving journey and experiences with this AWP. To date, it has been offered 3 times to 25 HCP over the course of 3 years. Among those responding to a post program follow up survey (N = 11), 8 (73%) indicated that they completed the project that they were working on during the AWP and went on to publish the manuscript (N = 5) or were in the process of submission (N = 2). Some indicated they has also gone on to present posters (N = 2) or were in the process of presenting posters (N = 2) or had received grants (N = 1) or were awaiting grant notice (N = 1). A number of attendees have continued to use and share the tools presented during the AWP. Based on input from attendees and increased requests for this AWP, this educational program has been deemed a success and expansion of this program is currently underway.
Stroke in the young
Kumar, Gyan

Mayo Clinic

The Biomedical & Life Sciences Collection | July 25, 2024 | Volume: 2021 | Issue: 3 | Pages: e1005135

10.69645/jzxa6483 Get It

Molecular Analysis of Persistent and Recurrent Barrett's Esophagus in the Setting of Endoscopic Therapy
Kumar, Aarti , Rara, Marianne , Wen, Kwun Wah , Grady, William M., Chak, Amitabh , Iyer, Prasad G. , Rustgi, Anil K. , Rubenstein, Joel H. , Liu, Yue , Kresty, Laura A. , Westerhoff, Maria , Kwon, Richard S. , Wamsteker, Erik, Wang, Tom, Berry, Lynne D. , Shaheen, Nicholas J. , Wang, Kenneth K, Stachler, Matthew D , Yu, Ming , Wang, Timothy C. , Canto, Marcia Irene , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | July 15, 2024 | Volume: 15 | Issue: 8 | Pages: e00751

10.14309/ctg.0000000000000751 | PMID 39007490 Get It

INTRODUCTION: Early neoplastic progression of Barrett's esophagus (BE) is often treated with endoscopic therapy. Although effective, some patients are refractory to therapy or recur after apparent eradication of the BE. The goal of this study was to determine whether genomic alterations within the treated BE may be associated with persistent or recurrent disease. METHODS: We performed DNA sequencing on pre-treatment esophageal samples from 45 patients who were successfully treated by endoscopic therapy and did not recur as well as pre-treatment and post-treatment samples from 40 patients who had persistent neoplasia and 21 patients who had recurrent neoplasia. The genomic alterations were compared between groups. RESULTS: The genomic landscape was similar between all groups. Patients with persistent disease were more likely to have pre-treatment alterations involving the receptor tyrosine kinase pathway ( P = 0.01), amplifications of oncogenes ( P = 0.01), and deletions of tumor suppressor genes ( P = 0.02). These associations were no longer significant after adjusting for patient age and BE length. More than half of patients with persistent (52.5%) or recurrent (57.2%) disease showed pre-treatment and post-treatment samples that shared at least 50% of their driver mutations. DISCUSSION: Pre-treatment samples were genomically similar between those who responded to endoscopic therapy and those who had persistent or recurrent disease, suggesting there is not a strong genomic component to treatment response. Although it was expected to find shared driver mutations in pre-treatment and post-treatment samples in patients with persistent disease, the finding that an equal number of patients with recurrent disease also showed this relation suggests that many recurrences represent undetected minimal residual disease.
Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy
Mehanna, Raja , Kumar, Kishore R. , Oosterbaan, Annelien M., Post, Bart , Ross, Owen A. , Piemonte, Maria Elisa Pimentel , Fraix, Valérie , Moro, Elena , Tan, Eng‐King , Savica, Rodolfo , Force, on behalf of the EOPD Task, Oosterbaan, Annelien , Ross, Owen A , Kumar, Kishore Raj , Pimentel Piemonte, Maria Elisa , Oosterbaan, Annelien M , Śmiłowska, Katarzyna , Fleisher, Jori , Alcalay, Roy N. , Marras, Connie , Force, on behalf of the EOPD Task

Mayo Clinic

Journal of Parkinson’s Disease | July 12, 2024 | Volume: 14 | Issue: 6 | Pages: 1277-1282

10.3233/jpd-240088 | PMID 38995803 Get It

Pregnancy in women with early-onset Parkinson’s disease (PD) is likely to have a higher frequency given the trend toward increasing maternal age, thus resulting in a greater overlap time between childbearing age and PD risk. Deep brain stimulation (DBS) therapy is nowadays offered to PD patients at earlier stage of the disease, when women can still be pre-menopausal. However, few data are available about DBS safety during pregnancy. From a review of the available literature, only one article was published on this topic so far. Therefore, we have developed a clinical consensus on the safety of DBS during pregnancy in PD patients.
Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients
Mikula, Anthony L. , Lakomkin, Nikita , Hamouda, Abdelrahman M. , Everson, Megan C., Pennington, Zach , Bydon, Mohamad , Kennel, Kurt A. , Freedman, Brett A. , Sebastian, Arjun S. , Anderson, Paul A. , Fogelson, Jeremy L. , Elder, Benjamin D. , Baffour, Francis , Pennington, Zach , Hamouda, Abdelrahman , Kumar, Rahul Robaish , Pinter, Zachariah W. , Martini, Michael L. , Nassr, Ahmad , Abode-Iyamah, Kingsley

Mayo Clinic

Journal of Neurosurgery: Spine | July 5, 2024 | Volume: 41 | Issue: 3 | Pages: 309-315

10.3171/2024.4.spine2424 | PMID 38968619 Get It

OBJECTIVE The purpose of this study was to determine the effect of osteoporosis medications on opportunistic CT-based Hounsfield units (HU). METHODS Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. HU were measured in the L1–4 vertebral bodies. One-way ANOVA was used to compare the mean change in HU among the five treatment regimens. RESULTS In total, 318 patients (70% women) were included, with a mean age of 69 years and mean BMI of 27 kg/m 2 . There was a significant difference in mean HU improvement (p < 0.001) following treatment with romosozumab for 3 to 12 months (n = 32), teriparatide for 3 to 12 months (n = 30), teriparatide for > 12 months (n = 44), denosumab for > 12 months (n = 123), and alendronate for > 12 months (n = 100). Treatment with romosozumab for a mean of 10.5 months significantly increased the mean HU by 26%, from a baseline of 85 to 107 (p = 0.012). Patients treated with teriparatide for > 12 months (mean 23 months) experienced a mean HU improvement of 25%, from 106 to 132 (p = 0.039). Compared with the mean baseline HU, there was no significant difference after treatment with teriparatide for 3 to 12 months (110 to 119, p = 0.48), denosumab for > 12 months (105 to 107, p = 0.68), or alendronate for > 12 months (111 to 113, p = 0.80). CONCLUSIONS Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
Features of Importance in Nasal Endoscopy: Deriving a Meaningful Framework
Babahaji, Layla M., Ganeshan, Vinayak , Nguyen, Thinh S., Ahmed, Omar G. , Barton, Blair M. , Halawi, Akaber, Joe, Stephanie, Marino, Michael J. , Patel, Zara M. , Rangarajan, Sanjeet V., Riley, Charles A. , Roxbury, Christopher R. , Tabaee, Abtin, Tang, Dennis M. , Wu, Arthur W. , Yim, Michael , Bidwell, Jonathan, Riley, Charles A. , McCoul, Edward D , Patel, Zara , Wu, Arthur W , Chandra, Rakesh Kumar , Chen, Philip G. , Gudis, David A. , Higgins, Thomas S , Kuan, Edward C , Ramakrishnan, Vijay R , McCoul, Edward D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 5, 2024 | Volume: 171 | Issue: 4 | Pages: 1052-1061

10.1002/ohn.889 | PMID 38967295 Get It

AbstractObjectiveCritical components of the nasal endoscopic examination have not been definitively established for either the normal examination or for clinical disorders. This study aimed to identify concordance among rhinologists regarding the importance of examination findings for various nasal pathologies.Study DesignA consortium of 19 expert rhinologists across the United States was asked to rank the importance of findings on nasal endoscopy for 5 different sinonasal symptom presentations.SettingAn online questionnaire was distributed in July 2023.MethodsThe questionnaire utilized JotForm® software and featured 5 cases with a set of 4 identical questions per case, each covering a common indication for nasal endoscopy. Rankings were synthesized into Normalized Attention Scores (NASs) and Weighted Normalized Attention Scores (W‐NASs) to represent the perceived importance of each feature, scaled from 0 to 1.ResultsGeneral concordance was found for examination findings on nasal endoscopy within each case. The perceived features of importance differed between cases based on clinical presentation. For instance, in evaluating postnasal drip, the middle meatus was selected as the most important structure to examine (NAS, 0.73), with mucus selected as the most important abnormal finding (W‐NAS, 0.66). The primary feature of interest for mucus was whether it was purulent or not (W‐NAS, 0.67). Similar analyses were performed for features in each case.ConclusionThe implicit framework existing among rhinologists may help standardize examinations and improve diagnostic accuracy, augment the instruction of trainees, and inform the development of artificially intelligent algorithms to enhance clinical decision‐making during nasal endoscopy.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Kumar, Anita , Hill, Brian T. , Danilov, Alexey V. , Pongas, Georgios , Greenwell, Irl Brian , Cohen, Jonathon B. , Martin, Peter , Wang, Yucai , Larson, Melissa C. , Bond, David A. , Kahl, Brad S. , Merryman, Reid W. , Grover, Natalie S. , Tun, Aung M. , Ayyappan, Sabarish Ram , Portell, Craig A. , Muñoz, Javier , Reagan, Patrick Michael , Moustafa, Muhamad Alhaj , Pophali, Priyanka A.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7006-7006

10.1200/jco.2024.42.16_suppl.7006 Get It

7006 Background: Rituximab maintenance (RM) after first-line (1L) bendamustine and rituximab (BR) in MCL did not improve progression-free survival in the MAINTAIN trial (Rummel et al, ASCO 2016) but was associated with improved survival outcomes in a North American observational study (Martin et al, JCO 2023). We sought to examine the potential benefit of RM after BR using a large observational cohort from 26 US academic centers. Methods: Patients with MCL who received 1L BR (without stem cell transplant) outside of clinical trials were included. At the landmark of 3 months after the end of BR, patients who achieved a complete response (CR) or partial response (PR) to BR and had no evidence of progressive disease (PD) or second-line (2L) therapy were deemed eligible for RM. Event-free survival (EFS) was defined as time from landmark to progression, relapse, retreatment, or death. EFS2 was defined as time from landmark to progression, relapse, or retreatment following 2L therapy or death. RM was not considered a line of therapy for either endpoint. OS was defined as time from landmark to death. Survival analysis was done with Kaplan-Meier methods and Cox regression models adjusting for sex and simplified MIPI. Results: Among 796 patients who received 1L BR in 2007-2020, 693 achieved a CR or PR. At the 3-month post-BR landmark, 613 had no evidence of PD, among whom 318 (52%) received RM and 295 did not. The RM group was younger (median age 70 vs 72, p = 0.010) and more predominantly male (78% vs 69%, p = 0.047). There was no statistical difference in stage, simplified MIPI, histology (blastoid or pleomorphic vs classic), Ki-67, TP53 alteration, complex karyotype, year of BR start, or best response to BR between the two groups. The median follow-up after the 3-month post-BR landmark was 61.3 months (95% CI 62.6-70.4). The median number of doses of RM was 10 (IQR 5-12). RM was associated with improved EFS (median 47.1 vs 29.7 months, adjusted HR 0.59, 95% CI 0.48-0.73), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.63, 95% CI 0.50-0.81), and OS (median 136.1 vs 74.3 months, adjusted HR 0.57, 95% CI 0.44-0.75) (all p values < 0.001). In patients with CR to 1L BR (n=527), 271 (51%) received RM, for a median of 11 (IQR 6-12) doses. In this subgroup, RM was associated with improved EFS (median 60.6 vs 31.5 months, adjusted HR 0.56, 95% CI 0.44-0.71), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.62, 95% CI 0.48-0.81), and OS (median 136.1 vs 75.6 months, adjusted HR 0.59, 95% CI 0.44-0.79) (all p values < 0.001). Analysis in patients with PR to 1L BR was limited by the sample size (n=86, 47 received RM). The numeric differences in median EFS (20.8 vs 11.5, log-rank p = 0.370), EFS2 (48.9 vs 30.3, log-rank p = 0.210) and OS (87.3 vs 46.9, log-rank p = 0.067) were not statistically significant. Conclusions: In this large multicenter study, RM after 1L BR was associated with improved EFS and OS, supporting its use in routine practice for patients with newly diagnosed MCL.